Metallo-Therapy is an Israeli start-up company founded in 2010 by Dr. Amal Ayoub. The company is developing novel contrast agents that enable precise tumor detection and monitoring using the CT imaging tool.

MT has developed proprietary gold nanoparticles (GNP), which accumulate in malignant tumors and retain in tumors for an extended period of a few weeks. Due to their low toxicity profile and unique characteristics, in addition to their contrasting function, the GNPs can function as nano markers, supporting and enhancing multiple applications in the management of cancer patients undergoing radiotherapy. 

Metallo-Therapy is supported by the Chief Scientist of the Israeli Ministry of Economy and by Arkin Holdings, an investment fund focused on innovative technologies in the healthcare market.

about

Metallo-Therapy: Gold nanoparticles for better cancer management
Copyright © 2016 Metallo-Therapy Ltd
Website by Sigalon